J.Molner
Company Announcement

J. Molner AS launches Lidocaine HCL Topical Solution USP, 4% in the United States

Tallinn, 2024-11-12 08:30 CET -- J. Molner AS (Nasdaq Tallinn: MOLNR) today announced the launch of its new product in the United States: Lidocaine HCL Topical Solution USP, 4%. The new product launch is a notable step in the company’s efforts to create an international platform for its pharmaceutical products.

The Lidocaine HCL Topical Solution, 4%, now available in the US, is a prescription-only medication intended for the production of anesthesia of accessible mucous membranes of the oropharynx. Detailed product information is available on the DailyMed website at
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=17880468-873f-6465-e063-6294a90a9c73&version=3

“Our launch of Lidocaine HCL Topical Solution, 4% is another step forward for J. Molner AS,” remarked Jason Grenfell-Gardner, Founder of J. Molner AS. This product, which was entirely developed in Estonia, reflects our commitment to meticulous planning and quality standards.”

J. Molner AS remains dedicated to steady growth and advancing pharmaceutical development to bring high-quality solutions to the market.

For additional information about J. Molner AS, please visit www.jmolner.com.

         For additional information please contact:
         
         Jason Grenfell-Gardner
         
         J. Molner AS
         Management Board member
         +372 536 00 346
         jason@jmolner.com